Longevity Supplements While on GLP-1: NMN, Berberine, and What's Worth It

The longevity supplement market is worth billions and contains a significant amount of noise. On GLP-1 therapy, the picture becomes interesting because you're already taking what may be one of the most impactful longevity interventions available without a clinical trial.

Semaglutide's cardiovascular data is compelling. The SELECT trial — 17,604 participants, mean follow-up 39.8 months — showed a 20% reduction in major cardiovascular events in people with obesity but without diabetes. That's a primary cardiovascular outcome, not a surrogate marker. SELECT was powered on hard endpoints, and semaglutide delivered.

The mechanism goes beyond weight loss: GLP-1 receptors are expressed in cardiac tissue and the vasculature, and semaglutide has direct anti-inflammatory, anti-atherosclerotic effects. The drug is doing longevity work that most supplements claim to do and don't.

That context matters when evaluating what to add. Some longevity compounds have complementary mechanisms and genuinely stack well. Others overlap so heavily with what GLP-1 already does that they add little value.

NMN and NAD+ Precursors

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are precursors to NAD+, a coenzyme essential for DNA repair, mitochondrial function, and sirtuin activation. NAD+ levels decline with age — by roughly 50% between age 40 and 60.

The theory: supplementing NMN or NR raises NAD+ levels, activating SIRT1 and SIRT3 (proteins involved in metabolic regulation, mitochondrial biogenesis, and stress resistance). Animal studies are consistently positive. Human clinical data is more limited but emerging.

How this stacks with GLP-1:

GLP-1 receptor agonists improve mitochondrial function in adipose and hepatic tissue through AMPK activation. NAD+ supports the same mitochondrial machinery through a distinct pathway (sirtuin activation). These are complementary, not redundant.

Where the stack becomes particularly interesting: caloric restriction — which GLP-1 effectively produces — is itself one of the most reliable NAD+-boosting interventions. GLP-1 is doing some of the NMN's job for free. But the two pathways (caloric restriction signalling via AMPK and direct NAD+ repletion via NMN/NR) are additive in animal models.

Dose: 250-500mg NMN or NR daily. Take in the morning — NAD+ has downstream effects on circadian rhythm and sleep when taken late.

Evidence quality: Mechanistically strong, human RCT data still maturing. A reasonable addition for people with a serious longevity focus, but with appropriate expectation calibration.

Berberine

Berberine is the most discussed longevity supplement in GLP-1 communities, largely because it's described as "nature's Ozempic." That comparison has enough truth in it to be useful and enough inaccuracy to be misleading.

Berberine activates AMPK — the same cellular energy sensor activated by caloric restriction and metformin — and has meaningful effects on blood glucose, insulin sensitivity, and lipid profiles. A meta-analysis of 46 RCTs (2,569 participants) found berberine reduced fasting glucose by 1.07 mmol/L, HbA1c by 0.51%, and LDL cholesterol by 0.65 mmol/L.

What it doesn't do: produce 15-20% weight loss. Berberine produces approximately 0.5-1.5kg of weight loss in most trials, largely through gut microbiome effects and reduced intestinal glucose absorption. The comparison to Ozempic is a marketing overstatement.

How this stacks with GLP-1:

Berberine and GLP-1 receptor agonists have partially overlapping mechanisms (both affect insulin signalling and glucose metabolism) but act through different pathways. Adding berberine to GLP-1 therapy is not redundant — the AMPK activation is additional to GLP-1 receptor signalling. The combination may produce additive improvements in insulin sensitivity and lipid profiles beyond GLP-1 alone.

The full berberine vs GLP-1 comparison is at Berberine vs GLP-1 UK.

Dose: 500mg three times daily with meals. Berberine has a short half-life and requires multiple daily doses.

Caution: Berberine interacts with several medications including warfarin, ciclosporin, and some statins. Check interactions with your prescriber before starting if you take other medications.

Resveratrol and Trans-Resveratrol

Resveratrol activates SIRT1 and SIRT3 and has been extensively studied in animal longevity research. The human data is more disappointing — poor oral bioavailability means standard resveratrol capsules deliver a fraction of the active compound systemically.

Trans-resveratrol, and particularly micronised or liposomal formulations, improves bioavailability. But even optimised resveratrol is less compelling than NMN as a sirtuin activator when you're already on caloric restriction.

On GLP-1: Lower priority than NMN or berberine. Skip unless you're already optimising NMN and want to add a sirtuin-focused layer.

Omega-3 (EPA/DHA)

Not exotic, but worth including: omega-3 has among the strongest longevity evidence of any supplement. The REDUCE-IT trial (8,179 participants) demonstrated a 25% reduction in major cardiovascular events with high-dose EPA over a median 4.9 years. GLP-1 already improves cardiovascular outcomes independently; omega-3 works through complementary mechanisms (triglyceride reduction, endothelial function, anti-inflammatory effects).

On GLP-1: High priority. The cardiovascular benefits stack well with GLP-1's own cardioprotective effects. See NHS Wegovy cardiovascular expansion for the policy context on GLP-1 and heart disease.

Dose: 1-2g combined EPA+DHA daily. High-dose (2-4g EPA specifically) for significant cardiovascular risk reduction.

Apigenin

Apigenin is a flavonoid that inhibits CD38 — an enzyme that degrades NAD+. This makes it synergistic with NMN: NMN increases NAD+ production while apigenin reduces NAD+ breakdown. The combination produces higher sustained NAD+ levels than either alone.

Human data is limited, but the mechanistic logic is sound and apigenin has a long safety record as a dietary compound (abundant in parsley, chamomile tea, and celery).

Dose: 50-100mg daily with NMN.

Spermidine

Spermidine induces autophagy — cellular self-cleaning — and has produced lifespan extension in multiple animal models. Observational data in humans associates higher dietary spermidine intake (from wheat germ, aged cheese, mushrooms) with reduced cardiovascular mortality.

On GLP-1: Potentially complementary. GLP-1's caloric restriction effect modestly activates autophagy. Spermidine activates autophagy through a distinct pathway (eIF5A hypusination). The combination is theoretically additive.

Evidence quality is lower than NMN or berberine in humans. Worth considering if budget allows after covering the essentials.

Priority Framework: What to Actually Buy

Given that GLP-1 already covers significant longevity ground (cardiovascular protection, metabolic reset, reduced inflammation), the incremental value of longevity supplements is:

Highest value additions:

1. Omega-3 (EPA/DHA) — complementary cardiovascular mechanism, strong evidence
2. Berberine — additional AMPK activation, lipid and glucose benefits
3. NMN + apigenin — NAD+ support, complementary to GLP-1's metabolic effects

Secondary additions: 4. Magnesium — sleep, insulin sensitivity, broadly important (see GLP-1 monitoring protocol) 5. Spermidine — autophagy, emerging evidence

Lower priority on GLP-1: 6. Resveratrol — bioavailability problems, better alternatives available 7. Rapamycin (controversial; prescription in UK) — out of scope here

See the full supplement overview at best supplements on GLP-1 2026.

For men specifically looking to optimise training and hormones alongside GLP-1 treatment, Male Optimal covers testosterone, training protocols, and bloodwork in detail.

Always consult your GP before adding supplements — particularly berberine, which has documented drug interactions — to your GLP-1 therapy regimen.